Novartis (NVS)

[debunker1]

Entresto will flop

All they've done is capitalize on the benefits of switching someone with CHF and COPD from and ACE inhibitor to an ARB, any ARB.

These days pretty much everyone with CHF also has COPD.

They are using a massive marketing campaign with many TV commercials to try and convince people that Entresto is something new when it's mainly comprised of the same drug (valsartan) that was their once big time seller they called DIOVAN, they recently lost patent protection on.

Their trial did not include a true head to head comparison of valsartan vs valsartan/sacubitril.

They try and convince people that using an ARB instead of an ACE inhibitor for CHF is something new, ARB's have been around for years and there are many examples from many companies.

Doctors and insurance companies will soon get wise to this and Entresto sales will plummet.

Never before in history has a pharma tried such an attempt at repackaging and re-patenting a drug that they lost patent protection on in this manner, people will catch on eventually.